Switch theme
Sign up to access all valuation multiples
PExA AB develops, manufactures, and markets a research tool for studying respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). Its product includes PExA 2.0.
2004
3
Last FY Revenue $0.1M
Last FY EBITDA -$1.0M
$1.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, PExA achieved revenue of $0.1M and an EBITDA of -$1.0M.
PExA expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PExA valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | XXX | $34K | XXX | XXX | XXX |
| Gross Margin | XXX | 45% | XXX | XXX | XXX |
| EBITDA | XXX | -$1.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -1368% | XXX | XXX | XXX |
| EBIT | XXX | -$1.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -1453% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.0M | XXX | XXX | XXX |
| Net Margin | XXX | -1412% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, PExA's stock price is SEK 0 (or $0).
PExA has current market cap of SEK 17.9M (or $1.8M), and EV of SEK 14.1M (or $1.5M).
See PExA trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5M | $1.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, PExA has market cap of $1.8M and EV of $1.5M.
PExA's trades at 19.5x EV/Revenue multiple, and -1.4x EV/EBITDA.
Equity research analysts estimate PExA's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PExA's P/E ratio is not available.
See valuation multiples for PExA and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8M | XXX | $1.8M | XXX | XXX | XXX |
| EV (current) | $1.5M | XXX | $1.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 19.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPExA's revenue per employee in the last FY averaged $25K, while opex per employee averaged $0.4M for the same period.
PExA's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PExA's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PExA and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1368% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $25K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1498% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PExA acquired XXX companies to date.
Last acquisition by PExA was XXXXXXXX, XXXXX XXXXX XXXXXX . PExA acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was PExA founded? | PExA was founded in 2004. |
| Where is PExA headquartered? | PExA is headquartered in Sweden. |
| How many employees does PExA have? | As of today, PExA has 3 employees. |
| Is PExA publicy listed? | Yes, PExA is a public company listed on SAT. |
| What is the stock symbol of PExA? | PExA trades under PEXA B ticker. |
| When did PExA go public? | PExA went public in 2015. |
| Who are competitors of PExA? | Similar companies to PExA include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of PExA? | PExA's current market cap is $1.8M |
| Is PExA profitable? | Yes, PExA is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
